Now Offering SPRAVATO Treatment
For Adults with Treatment-Resistant Depression
A new FDA-approved nasal spray treatment, available at Valor Health for adults struggling with depression that hasn’t responded to traditional medication.
Book a ConsultationWhat Is SPRAVATO?
(esketamine) CIII nasal spray is an FDA-approved medication used in combination with an oral antidepressant to treat:
- Adults with treatment-resistant depression (TRD)
- Adults with major depressive disorder (MDD) experiencing suicidal thoughts or behavior
- Patients who have tried two or more antidepressants without relief
- Patients who may benefit from a fast-acting treatment option under medical supervision
How the Treatment Works
A Different Approach to Depression Treatment
SPRAVATO may offer an alternate path for those who have tried two or more antidepressants without success.
It is administered in-office and initially taken twice a week, then tapering to once a week or every other week.
Is SPRAVATO Right for You?
SPRAVATO might be a good fit if:
- You’ve been diagnosed with treatment-resistant depression (TRD)
- You’ve tried at least two other antidepressants without sufficient relief
- You’re under the care of a healthcare provider who can coordinate your treatment
- You’re looking for a monitored treatment administered in a clinical setting
Important Safety Information
SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness as an anesthetic have not been established.
Please note: SPRAVATO is only available through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered in a certified medical facility under supervision.
More Safety InformationAffiliation
